Randomized, placebo-controlled, double-blind trial to study the effects of polidocanol on experimental pruritus
Not Applicable
- Conditions
- L29Pruritus
- Registration Number
- DRKS00004279
- Lead Sponsor
- Klinik für Dermatologie und AllergologieCharité - Universitätsmedizin Berlin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Healthy individuals
Exclusion Criteria
Pregnancy, breast feeding, skin diseases, diseases of the peripheral nervous system, intake of antihistamines, NSAIDs, local anesthetics or mast cell stabilizers within 5 days prior to testing, intake of antideppressants within 14 days prior to testing, intake of steroids (topical or systemic) within 7 days prior to testing.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the effect of 3% Polidocanol on pruritus induced by Mucuna pruriens (cowhage) by itch intensity (VAS) within 30 minutes after Mucuna application
- Secondary Outcome Measures
Name Time Method - To assess the effect of 3% Polidocanol on pruritus induced by histamine (by VAS for 30 minutes)<br>- To assess the effect of 3% Polidocanol on wheal development, flare development, and change in blood flow induced by Mucuna pruriens (cowhage). Wheal development will be assessed by measuring wheal diameter (mean of the largest diameter and the perpendicular diameter) and volumetry of the wheal using digital volumetric measurements 15 and 30 minutes after provocation. Flare will be measured in extent by measuring flare diameter (mean of the largest diameter and the perpendicular diameter) and in intensity using a mexameter 15 and 30 minutes after provocation. <br>- To assess the effect of 3% Polidocanol on wheal development, flare development, and change in blood flow induced by histamine as described above<br>